L -DOPA-induced dyskinesia (LID) represents one of the major limitations in the current pharmacotherapy of Parkinson's disease (PD) and affects the majority of PD patients. Animal models are the most important preclinical tool for molecular investigations of LID mechanisms and therapeutic targets. Over the last two decades, models of LID have been developed in both nonhuman primate and rodent species, recapitulating several aspects of the human dyskinesia. This chapter will review and compare the main features of the rodent and nonprimate models of LID currently available and summarize some of the main neurobiological fi ndings obtained from these models
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
L-DOPA-induced dyskinesia (LID) is a significant complication of dopamine replacement therapy in Par...
With the advent of rodent models of l-DOPA-induced dyskinesia (LID), a growing literature has linked...
L-DOPA-induced dyskinesia (LID) is a major complication of the pharmacotherapy of Parkinson's diseas...
Appearance of l-DOPA-induced dyskinesia (LID) represents a major limitation in the pharmacological t...
A common side effect of the pharmacotherapy for treatment of the movement disorder Parkinson’s disea...
Major limitations to the pharmacotherapy of Parkinson's disease (PD) are the motor complications res...
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ab...
Strategies to avoid or minimize dyskinesia and other motor complications of chronic dopamine replace...
Copyright © Experimental Neurobiology 2020. Motor symptoms in Parkinson\u27s disease (PD) are direct...
Animal models of Parkinson’s disease and L-DOPA-induced dyskinesia are essential to explore pathophy...
An increasing body of experimental evidence suggests that serotonergic neurons play a major role in ...
Parkinson’s disease is a movement disorder, caused predominantly by the degeneration of the dopamine...
The work presented in herein focuses on the optimisation and use of established animal models to stu...
Background Several different animal models are currently used to research the neurodegenerative move...
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
L-DOPA-induced dyskinesia (LID) is a significant complication of dopamine replacement therapy in Par...
With the advent of rodent models of l-DOPA-induced dyskinesia (LID), a growing literature has linked...
L-DOPA-induced dyskinesia (LID) is a major complication of the pharmacotherapy of Parkinson's diseas...
Appearance of l-DOPA-induced dyskinesia (LID) represents a major limitation in the pharmacological t...
A common side effect of the pharmacotherapy for treatment of the movement disorder Parkinson’s disea...
Major limitations to the pharmacotherapy of Parkinson's disease (PD) are the motor complications res...
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ab...
Strategies to avoid or minimize dyskinesia and other motor complications of chronic dopamine replace...
Copyright © Experimental Neurobiology 2020. Motor symptoms in Parkinson\u27s disease (PD) are direct...
Animal models of Parkinson’s disease and L-DOPA-induced dyskinesia are essential to explore pathophy...
An increasing body of experimental evidence suggests that serotonergic neurons play a major role in ...
Parkinson’s disease is a movement disorder, caused predominantly by the degeneration of the dopamine...
The work presented in herein focuses on the optimisation and use of established animal models to stu...
Background Several different animal models are currently used to research the neurodegenerative move...
Parkinson‘s disease (PD) is a progressive and disabling neurodegenerative disease, characterized by ...
L-DOPA-induced dyskinesia (LID) is a significant complication of dopamine replacement therapy in Par...
With the advent of rodent models of l-DOPA-induced dyskinesia (LID), a growing literature has linked...